Therefore, consistent with previous findings (Soria et al, 2018), gain‐of‐function mutation of the autophagy activator Becn1 protects against acute hyperammonemia in vivo, suggesting that Beclin‐1 is a druggable candidate for therapy of hyperammonemia. Here, BECN1 is linked to Hyperammonemia.